Brief: Baudax Bio Gives Positive Results From 2nd Interim Analysis Of Phase 2 Randomized Trial For BX1000
27/03/2023 13:45
March 27 (Reuters) - Baudax Bio Inc BXRX.O :
* BAUDAX BIO ANNOUNCES POSITIVE RESULTS FROM 2ND INTERIM
ANALYSIS
OF PHASE 2 RANDOMIZED TRIAL FOR BX1000
* BAUDAX BIO INC - TOP LINE RESULTS EXPECTED LATE
APRIL/EARLY MAY
* BAUDAX BIO INC - CLINICAL TRIAL IS EVALUATING SAFETY AND
TOLERABILITY PROFILE OF BX1000 AND ROCURONIUM IN THIS PATIENT
POPULATION
Source text for Eikon: ID:nGNX9N5WVf
Further company coverage: BXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer